Pancreatic cancer is one of the most lethal malignancies in the world.Cancer-associated fibroblasts are one of the main components of tumor microenvironment in pancreatic cancer and play an essential role in tumor pro...Pancreatic cancer is one of the most lethal malignancies in the world.Cancer-associated fibroblasts are one of the main components of tumor microenvironment in pancreatic cancer and play an essential role in tumor progression.Fibroblast activation protein that is expressed in specific subtypes of cancer-associated fibroblasts promotes tumor growth and is related to poor survival.Recent researches have preliminarily demonstrated a promising potential of radiopharmaceuticals targeting fibroblast activation protein in diagnosis and therapy of pancreatic cancer.This article comprehensively reviews the current development and clinical translation of fibroblast activation protein inhibitor-targeting radiopharmaceuticals in pancreatic cancer and provides significant perspectives for future investigations.展开更多
基金This work was in part supported by the National Natural Science Foundation of China(No.82071967)CAMS Innovation Fund for Medical Science(No.CIFMS-2021-I2M-1-025)+2 种基金National Key Research and Development Program of China(No.2016YFC0901500)CAMS Fund for Rare Diseases Research(No.2016ZX310174-4)Tsinghua university and PUMCH Joint Fund(No.PTQH201906006).
文摘Pancreatic cancer is one of the most lethal malignancies in the world.Cancer-associated fibroblasts are one of the main components of tumor microenvironment in pancreatic cancer and play an essential role in tumor progression.Fibroblast activation protein that is expressed in specific subtypes of cancer-associated fibroblasts promotes tumor growth and is related to poor survival.Recent researches have preliminarily demonstrated a promising potential of radiopharmaceuticals targeting fibroblast activation protein in diagnosis and therapy of pancreatic cancer.This article comprehensively reviews the current development and clinical translation of fibroblast activation protein inhibitor-targeting radiopharmaceuticals in pancreatic cancer and provides significant perspectives for future investigations.
